What is known? * the impact of AZA, immunomodulatory drug widely used in active CD, on the intestinal wall differs from those of steroids, what is reflected in the significant difference in the postoperative anastomotic leaks rate * AZA inhibits intestinal epithelial cell growth by inducing the apoptosis and inhibiting proliferation of intestinal epithelial cells in in vitro studies What is new? * The effect of AZA on cellular damage was assessed in humans' study * AZA increases cell apoptosis in the intestinal epithelium of active CD patients, much stronger than steroids * AZA actively promotes the DNA damage repair in the intestinal epithelium; the steroid effect, even when combined with AZA, is not so pronounced * The intensity of proliferative processes, in contrast to steroids, is significantly inhibited in response to AZA * The disintegration of the mucosa layer in response to AZA is observed * The difference in the mechanisms of action of AZA and steroids on the intestinal mucosa may be directly related to the reported difference in the risk of septic postoperative complications, but this requires further research
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
histopathological assessment of the azathioprine's impact on intestinal damage
Timeframe: 30 days